⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CAMP News
CAMP4 Therapeutics Corporation Common Stock
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
globenewswire.com
CAMP
CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026
globenewswire.com
CAMP
CAMP4 to Participate in Upcoming Investor Conferences
globenewswire.com
CAMP
Form 8-K
sec.gov
CAMP
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights
globenewswire.com
CAMP
Form 8-K
sec.gov
CAMP
CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement
globenewswire.com
CAMP
Form 8-K
sec.gov
CAMP
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
globenewswire.com
CAMP
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CAMP